Last reviewed · How we verify
NCT03903211
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
Phase 2 trial testing [18F]PI-2620 in Cognitively Normal in 84 participants. Completed in 28 February 2021.
28 February 2021
Quick facts
| Lead sponsor | Jae Seung Kim |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 84 |
| Start date | 9 April 2019 |
| Primary completion | 28 February 2021 |
| Estimated completion | 28 February 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- [18F]PI-2620
Conditions studied
- Cognitively Normal — all drugs for Cognitively Normal →
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
Jae Seung Kim
Who can join
Adults 40 to 85, any sex, with Cognitively Normal or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03903211
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of [18F]PI-2620
Trials testing the same drug.
- NCT05337774 — Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury · Phase 1 · terminated
- NCT04566003 — Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition · Phase 1 · completed
- NCT03510572 — Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in t · EARLY_PHASE1 · completed
Other recruiting trials for Cognitively Normal
Currently open trials in the same condition.
- NCT06127667 — Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan · NA · recruiting
Other Jae Seung Kim trials
Trials by the same sponsor.
- NCT02656498 — [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03903211 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jae Seung Kim
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03903211.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing